The authors of this review, published in the March 2023 issue, requested to clarify the following sentence:

“In COPD, TSLP production in bronchial epithelial cells may be mediated by Th17, suggesting that anticholinergics may exert an anti-inflammatory effect in COPD via TSLP [111] and that the role of TSLP in COPD may be more limited to airway smooth muscles.”

This has been corrected to read:

“In COPD, TSLP production in bronchial epithelial cells and involvement in releasing acetylcholine may be mediated by Th17, suggesting that anticholinergics may exert an anti-inflammatory effect in COPD via TSLP [111] and that the role of TSLP in COPD may be more limited to airway smooth muscles.”

In addition, in table 1 the Key results summary for the entry NCT03347279 [117] NAVIGATOR study Tezepelumab (anti-TSLP) has been corrected based on information presented in reference 117 in the review. The published table summary read:

“66% exacerbation rate reduction (p<0.001), FEV1 improvement of 0.13 L (p<0.001) for 210 mg dose in comparison with placebo”

This has been corrected to:

“56% exacerbation rate reduction (p<0.001), FEV1 improvement of 0.13 L (p<0.001) for 210 mg dose in comparison with placebo”

Finally, a minor typographical error has been corrected in the first sentence of the section Insights from clinical trials. The sentence now reads:

“Within the last 10 years, trials with biological drugs targeting the IL-33/ST2 and anti-TSLP pathways in asthma and COPD have been and continue to be undertaken (table 1).”

The article has been corrected and republished online.